Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Cancer Lett
    November 2024
  1. LIU R, Zou Z, Zhang Z, He H, et al
    Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC.
    Cancer Lett. 2024;605:217286.
    >> Share

  2. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
    PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
    Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
    >> Share

    October 2024
  3. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
    Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
    Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
    >> Share

    August 2024
  4. HE Q, Zhang Y, Li W, Chen S, et al
    Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    Cancer Lett. 2024;602:217214.
    >> Share

  5. WANG X, Zhang L, Cheng L, Wang Y, et al
    Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities and Challenges.
    Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184.
    >> Share

  6. LIU D, Wang L, Guo Y
    Advances in and Prospects of Immunotherapy for Prostate Cancer.
    Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155.
    >> Share

    June 2024
  7. LIU YN, Liu MK, Wen YC, Li CH, et al
    Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
    Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090.
    >> Share

  8. CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al
    Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in Prostate Cancer.
    Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063.
    >> Share

  9. LIU C, Chen J, Cong Y, Chen K, et al
    PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068.
    >> Share

  10. CHEN HJ, Yu MM, Huang JC, Lan FY, et al
    SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
    Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
    >> Share

    May 2024
  11. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    >> Share

    March 2024
  12. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    >> Share

  13. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    >> Share

    February 2024
  14. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    >> Share

  15. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    >> Share

  16. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    >> Share

  17. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    >> Share

    January 2024
  18. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    >> Share

    November 2023
  19. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    >> Share

    October 2023
  20. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    >> Share

    September 2023
  21. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    >> Share

    August 2023
  22. NADERINEZHAD S, Zhang G, Wang Z, Zheng D, et al
    A novel GRK3-HDAC2 regulatory pathway is a key direct link between neuroendocrine differentiation and angiogenesis in prostate cancer progression.
    Cancer Lett. 2023 Aug 3:216333. doi: 10.1016/j.canlet.2023.216333.
    >> Share

    July 2023
  23. WANG F, Liu S, Liu F, Xu T, et al
    TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
    Cancer Lett. 2023;568:216300.
    >> Share

    May 2023
  24. GAO K, Li X, Ni J, Wu B, et al
    Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer.
    Cancer Lett. 2023 May 30:216247. doi: 10.1016/j.canlet.2023.216247.
    >> Share

  25. ZHANG Y, Fan A, Li Y, Liu Z, et al
    Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer.
    Cancer Lett. 2023 May 25:216244. doi: 10.1016/j.canlet.2023.216244.
    >> Share

  26. WILLIAMS A, Gutgesell L, de Wet L, Selman P, et al
    SOX(2) expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis.
    Cancer Lett. 2023 May 9:216209. doi: 10.1016/j.canlet.2023.216209.
    >> Share

    April 2023
  27. HAN H, Li H, Ma Y, Zhao Z, et al
    Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
    Cancer Lett. 2023 Apr 17:216188. doi: 10.1016/j.canlet.2023.216188.
    >> Share

    December 2022
  28. SU S, You S, Wang Y, Tamukong P, et al
    PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration.
    Cancer Lett. 2022 Dec 9:216034. doi: 10.1016/j.canlet.2022.216034.
    >> Share

    November 2022
  29. FENG J, Xi Z, Jiang X, Li Y, et al
    Saikosaponin a enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
    Cancer Lett. 2022 Nov 25:216011. doi: 10.1016/j.canlet.2022.216011.
    >> Share

  30. LACOMBE L, Hovington H, Brisson H, Mehdi S, et al
    UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.
    Cancer Lett. 2022 Nov 4:215994. doi: 10.1016/j.canlet.2022.215994.
    >> Share

    October 2022
  31. CHUA CW, Kruithof-de Julio M
    Exploring prostate cancer in the post-genomic era.
    Cancer Lett. 2022;553:215992.
    >> Share

    September 2022
  32. LIU J, Dong L, Zhu Y, Dong B, et al
    Prostate cancer treatment - China's perspective.
    Cancer Lett. 2022 Sep 23:215927. doi: 10.1016/j.canlet.2022.215927.
    >> Share

  33. FERGUSON AM, Rubin MA
    Lineage plasticity in prostate cancer: Looking beyond intrinsic alterations.
    Cancer Lett. 2022 Sep 5:215901. doi: 10.1016/j.canlet.2022.215901.
    >> Share

    August 2022
  34. JIAO J, Zhang J, Li Z, Wen W, et al
    Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot.
    Cancer Lett. 2022 Aug 23:215883. doi: 10.1016/j.canlet.2022.215883.
    >> Share

    July 2022
  35. ZHANG J, Li S, Zhang J, Zhang W, et al
    Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
    Cancer Lett. 2022 Jul 19:215829. doi: 10.1016/j.canlet.2022.215829.
    >> Share

    June 2022
  36. CHUA CW, Kruithof-de Julio M
    Featuring the guest editors for the Special Issue on Prostate Cancer, Cancer Letters.
    Cancer Lett. 2022;544:215807.
    >> Share

  37. MAI CW, Chin KY, Foong LC, Pang KL, et al
    Modeling prostate cancer: What does it take to build an ideal tumor model?
    Cancer Lett. 2022;543:215794.
    >> Share

    May 2022
  38. LORENZONI M, De Felice D, Beccaceci G, Di Donato G, et al
    ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3beta dependent Nkx3.1 degradation.
    Cancer Lett. 2022;534:215612.
    >> Share

    April 2022
  39. PAPACHRISTODOULOU A, Abate-Shen C
    Precision intervention for prostate cancer: Re-evaluating who is at risk.
    Cancer Lett. 2022 Apr 28:215709. doi: 10.1016/j.canlet.2022.215709.
    >> Share

    March 2022
  40. FONTANA F, Anselmi M, Limonta P
    Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy.
    Cancer Lett. 2022 Mar 8:215619. doi: 10.1016/j.canlet.2022.215619.
    >> Share

    February 2022
  41. DENG W, Zhou X, Zhu K, Chen R, et al
    Novel circular RNA circ_0086722 drives tumor progression by regulating the miR-339-5p/STAT5A axis in prostate cancer.
    Cancer Lett. 2022;533:215606.
    >> Share

  42. MIRO C, Di Giovanni A, Murolo M, Cicatiello AG, et al
    Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer.
    Cancer Lett. 2022 Feb 5:215581. doi: 10.1016/j.canlet.2022.215581.
    >> Share

  43. LOWDER D, Rizwan K, McColl C, Paparella A, et al
    Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.
    Cancer Lett. 2022 Feb 2. pii: S0304-3835(22)00044.
    >> Share

  44. CHEN H, Miao Y, Bian A, Ye J, et al
    A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth.
    Cancer Lett. 2022;532:215580.
    >> Share

    January 2022
  45. BAEK DS, Kim YJ, Vergara S, Conard A, et al
    A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Cancer Lett. 2022;525:97-107.
    >> Share

  46. CROWLEY L, Shen MM
    Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies.
    Cancer Lett. 2022;525:108-114.
    >> Share

  47. CHALLASIVAKANAKA S, Vickman RE, Kakarla M, Hayward SW, et al
    Fibroblast heterogeneity in prostate carcinogenesis.
    Cancer Lett. 2022;525:76-83.
    >> Share

  48. KANG J, La Manna F, Bonollo F, Sampson N, et al
    Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
    Cancer Lett. 2022 Jan 17. pii: S0304-3835(22)00023.
    >> Share

  49. QIAN C, Li D, Chen Y
    ETS factors in prostate cancer.
    Cancer Lett. 2022 Jan 13. pii: S0304-3835(22)00017.
    >> Share

  50. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    >> Share

    December 2021
  51. BERNASOCCHI T, Theurillat JP
    SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Cancer Lett. 2021;529:11-18.
    >> Share

  52. MARHOLD M, Kramer G, Krainer M, Le Magnen C, et al
    The prostate cancer landscape in Europe: Current challenges, future opportunities.
    Cancer Lett. 2021 Dec 1. pii: S0304-3835(21)00606.
    >> Share

  53. CHIODELLI P, Coltrini D, Turati M, Cerasuolo M, et al
    FGFR blockade by pemigatinib treats naive and castration resistant prostate cancer.
    Cancer Lett. 2021;526:217-224.
    >> Share

  54. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    >> Share

    November 2021
  55. SHI M, Wang Y, Lin D, Wang Y, et al
    Patient-derived xenograft models of neuroendocrine prostate cancer.
    Cancer Lett. 2021;525:160-169.
    >> Share

  56. SU S, Cao J, Meng X, Liu R, et al
    Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
    Cancer Lett. 2021 Nov 6. pii: S0304-3835(21)00558.
    >> Share

  57. HAQ S, Sarodaya N, Karapurkar JK, Suresh B, et al
    CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
    Cancer Lett. 2021;525:146-157.
    >> Share

    October 2021
  58. WANG C, Zhang Y, Gao WQ
    The evolving role of immune cells in prostate cancer.
    Cancer Lett. 2021 Oct 26. pii: S0304-3835(21)00545.
    >> Share

  59. FLORES-TELLEZ TDNJ, Baena E
    Experimental challenges to modeling prostate cancer heterogeneity.
    Cancer Lett. 2021;524:194-205.
    >> Share

  60. TOIVANEN R, Porter LH, Li Z, Clouston D, et al
    Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.
    Cancer Lett. 2021;524:182-192.
    >> Share

  61. WANG S, Chao F, Zhang C, Han D, et al
    Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer.
    Cancer Lett. 2021;524:109-120.
    >> Share

  62. MUGONI V, Ciani Y, Nardella C, Demichelis F, et al
    Circulating RNAs in prostate cancer patients.
    Cancer Lett. 2021;524:57-69.
    >> Share

  63. CACKOWSKI FC, Heath EI
    Prostate cancer dormancy and recurrence.
    Cancer Lett. 2021 Oct 5. pii: S0304-3835(21)00498.
    >> Share

  64. KANAGASABAI T, Li G, Shen TH, Gladoun N, et al
    MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00502.
    >> Share

    September 2021
  65. TIAN P, Zhong M, Wei GH
    Mechanistic insights into genetic susceptibility to prostate cancer.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
    >> Share

  66. RUIZ DE PORRAS V, Font A, Aytes A
    Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
    Cancer Lett. 2021 Sep 10. pii: S0304-3835(21)00430.
    >> Share

    August 2021
  67. WANG Y, Yu J
    Dissecting multiple roles of SUMOylation in prostate cancer.
    Cancer Lett. 2021;521:88-97.
    >> Share

  68. LI Q, Ye L, Zhang X, Wang M, et al
    Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
    Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.
    >> Share

    July 2021
  69. CAMPBELL KJ, Leung HY
    Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
    Cancer Lett. 2021 Jul 31. pii: S0304-3835(21)00378.
    >> Share

  70. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    >> Share

  71. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    >> Share

    June 2021
  72. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    >> Share

  73. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    >> Share

    May 2021
  74. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    >> Share

  75. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    >> Share

  76. HUANG SB, Thapa D, Munoz AR, Hussain SS, et al
    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
    Cancer Lett. 2021;505:24-36.
    >> Share

    February 2021
  77. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    >> Share

    January 2021
  78. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016